Latest news with #DouglasMiehm
Yahoo
2 days ago
- Business
- Yahoo
RBC Capital Lowered the PT on MannKind Corporation (MNKD), Kept a Buy Rating
MannKind Corporation (NASDAQ:MNKD) is one of the . On July 23, RBC Capital's analyst Douglas Miehm lowered the firm's price target on MannKind Corporation (NASDAQ:MNKD) from $10 to $8, while maintaining a Buy rating on the stock. The analyst believes the current stock price reflects an overly pessimistic view of MannKind Corporation (NASDAQ:MNKD)'s products, particularly the Tyvaso DPI royalties, and assigns no value to the company's product pipeline. During the fiscal first quarter of 2025, the company noted that its Afrezza, an inhaled insulin, saw 20% new prescription growth and 14% total prescription growth year-over-year. Moreover, the insulin's pediatric Phase 3 trial is progressing, and the company also met with the FDA's plan file for its approval in mid-2025. A close-up of a doctor's hand pressing on an inhaler, conveying the effect of the company's therapeutic products. MannKind Corporation (NASDAQ:MNKD) develops and sells inhaled therapeutic products for diabetes and rare lung diseases. While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Business Insider
14-06-2025
- Business
- Business Insider
RBC Capital Remains a Buy on DRI Healthcare (DHT.UN)
RBC Capital analyst Douglas Miehm maintained a Buy rating on DRI Healthcare ( – Research Report) on June 12 and set a price target of C$19.00. The company's shares closed yesterday at C$13.33. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Miehm covers the Healthcare sector, focusing on stocks such as WELL Health Technologies Corp, Knight Therapeutics, and Bausch + Lomb Corporation. According to TipRanks, Miehm has an average return of -1.7% and a 41.61% success rate on recommended stocks. Currently, the analyst consensus on DRI Healthcare is a Strong Buy with an average price target of C$17.00. The company has a one-year high of C$16.26 and a one-year low of C$10.39. Currently, DRI Healthcare has an average volume of 42.45K. Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of in relation to earlier this year.
Business Insider
15-05-2025
- Business
- Business Insider
RBC Capital Sticks to Their Buy Rating for DRI Healthcare (DHT.UN)
RBC Capital analyst Douglas Miehm maintained a Buy rating on DRI Healthcare ( – Research Report) yesterday and set a price target of C$18.00. The company's shares closed yesterday at C$12.48. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Miehm covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Ligand Pharma, and Bausch Health Companies. According to TipRanks, Miehm has an average return of -2.3% and a 39.85% success rate on recommended stocks. Currently, the analyst consensus on DRI Healthcare is a Strong Buy with an average price target of C$16.67, a 33.57% upside from current levels. In a report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a C$17.00 price target.
